Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-900-4520
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees49
Next Earnings Date5/2/2019 (Estimated)
OptionableNot Optionable
Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions
What is Corvus Pharmaceuticals' stock symbol?
Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."
How were Corvus Pharmaceuticals' earnings last quarter?
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) announced its quarterly earnings data on Thursday, March, 7th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.46) by $0.10. View Corvus Pharmaceuticals' Earnings History.
When is Corvus Pharmaceuticals' next earnings date?
What price target have analysts set for CRVS?
4 brokers have issued 12 month price targets for Corvus Pharmaceuticals' shares. Their predictions range from $11.00 to $17.00. On average, they anticipate Corvus Pharmaceuticals' share price to reach $14.3333 in the next year. This suggests a possible upside of 262.9% from the stock's current price. View Analyst Price Targets for Corvus Pharmaceuticals.
What is the consensus analysts' recommendation for Corvus Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corvus Pharmaceuticals.
Has Corvus Pharmaceuticals been receiving favorable news coverage?
News stories about CRVS stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Corvus Pharmaceuticals earned a coverage optimism score of 1.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Who are some of Corvus Pharmaceuticals' key competitors?
Some companies that are related to Corvus Pharmaceuticals include BioSpecifics Technologies (BSTC), Corium International (CORI), Corbus Pharmaceuticals (CRBP), Collegium Pharmaceutical (COLL), CytomX Therapeutics (CTMX), Cytokinetics (CYTK), ProQR Therapeutics (PRQR), Kalvista Pharmaceuticals (KALV), NuCana (NCNA), Five Prime Therapeutics (FPRX), Prothena (PRTA), Cyclerion Therapeutics (CYCN), Assembly Biosciences (ASMB), INDIVIOR PLC/S (INVVY) and Dynavax Technologies (DVAX).
What other stocks do shareholders of Corvus Pharmaceuticals own?
Who are Corvus Pharmaceuticals' key executives?
Corvus Pharmaceuticals' management team includes the folowing people:
- Dr. Richard A. Miller, Co-Founder, Pres, CEO & Chairman (Age 68)
- Mr. Leiv Lea, Chief Financial Officer (Age 65)
- Mr. Daniel W. Hunt J.D., Sr. VP & Chief Bus. Officer (Age 57)
- Dr. Joseph J. Buggy, Co-Founder & Exec. VP of Discovery Research (Age 52)
- Dr. William Benton Jones, Sr. VP of Pharmaceutical Devel. (Age 53)
When did Corvus Pharmaceuticals IPO?
(CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.
Who are Corvus Pharmaceuticals' major shareholders?
Corvus Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Raymond James Trust N.A. (0.04%). Company insiders that own Corvus Pharmaceuticals stock include Adams Street Partners Llc, Holdings A/S Novo, Leiv Lea and Richard A Md Miller. View Institutional Ownership Trends for Corvus Pharmaceuticals.
Which institutional investors are buying Corvus Pharmaceuticals stock?
CRVS stock was purchased by a variety of institutional investors in the last quarter, including Raymond James Trust N.A.. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Adams Street Partners Llc, Holdings A/S Novo, Leiv Lea and Richard A Md Miller. View Insider Buying and Selling for Corvus Pharmaceuticals.
How do I buy shares of Corvus Pharmaceuticals?
Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corvus Pharmaceuticals' stock price today?
One share of CRVS stock can currently be purchased for approximately $3.95.
How big of a company is Corvus Pharmaceuticals?
Corvus Pharmaceuticals has a market capitalization of $115.85 million. Corvus Pharmaceuticals employs 49 workers across the globe.
What is Corvus Pharmaceuticals' official website?
How can I contact Corvus Pharmaceuticals?
Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]
MarketBeat Community Rating for Corvus Pharmaceuticals (NASDAQ CRVS)
MarketBeat's community ratings are surveys of what our community members think about Corvus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
